Christine Mikail Cvijic Sells 739 Shares of Neurogene (NASDAQ:NGNE) Stock

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 739 shares of the business’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $34.06, for a total value of $25,170.34. Following the completion of the transaction, the chief financial officer directly owned 92,901 shares of the company’s stock, valued at approximately $3,164,208.06. This trade represents a 0.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Thursday, July 2nd, Christine Mikail Cvijic sold 4,061 shares of Neurogene stock. The stock was sold at an average price of $34.82, for a total value of $141,404.02.
• On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The shares were sold at an average price of $31.25, for a total transaction of $300,000.00.

Neurogene Stock Performance

NASDAQ:NGNE opened at $35.34 on Friday. Neurogene Inc. has a 12-month low of $15.93 and a 12-month high of $37.27. The firm has a market cap of $558.37 million, a price-to-earnings ratio of -7.77 and a beta of 1.68. The company’s 50-day moving average is $29.39 and its two-hundred day moving average is $23.33.

Neurogene (NASDAQ:NGNE) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($1.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.09). On average, equities research analysts forecast that Neurogene Inc. will post -5.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Neurogene

Hedge funds have recently modified their holdings of the stock. BNP Paribas Financial Markets grew its holdings in Neurogene by 89.8% in the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after purchasing an additional 978 shares during the period. Daiwa Securities Group Inc. purchased a new position in Neurogene during the fourth quarter worth approximately $66,000. PNC Financial Services Group Inc. boosted its holdings in shares of Neurogene by 24.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 5,055 shares of the company’s stock valued at $88,000 after purchasing an additional 1,000 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Neurogene by 17.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock valued at $82,000 after purchasing an additional 1,059 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Neurogene during the 4th quarter valued at $165,000. 52.37% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on NGNE shares. UBS Group set a $70.00 price target on Neurogene in a report on Wednesday, June 3rd. Canaccord Genuity Group decreased their price objective on Neurogene to $180.00 and set a “buy” rating on the stock in a report on Monday, April 6th. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price objective on shares of Neurogene in a research report on Tuesday, June 9th. Guggenheim began coverage on Neurogene in a research note on Tuesday, April 28th. They issued a “buy” rating and a $69.00 target price for the company. Finally, Rodman & Renshaw began coverage on Neurogene in a research report on Wednesday, June 3rd. They set a “buy” rating and a $70.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $84.83.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.